Home
Life Sciences
Pharmaceutical
Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition

Pharmaceutical

Summary

Table of Contents

Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition

Publication date: September 2010

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the largest achievements for therapeutic vaccine treatment of cancer—the approval of prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was a decade a go merely a speculative area.

Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope. Despite setbacks many developers are hopeful of a turnaround. With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.

This Kalorama Information report - New Developments in the Cancer Vaccine Market, 2010 - focuses on both preventive and therapeutic cancer vaccines in development. Cancers with vaccine development or potential are profiled in this report, some of these include:

Cervical

Colon/Rectal

Lung

Lymphoma

Melanoma

Prostate

Breast

Gastrointestinal

Renal

Brain

Bladder

Ovarian

Leukemia

The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there is current vaccines development are profiled. Each market segment provides an overview, descriptions of products available or in development, market estimates and forecasts for 2010-2015, and competitive analysis of leading developers for 2015.

The report also includes current issues and trends affecting the industry.

This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.

Issues and trends discussed in The Emerging Cancer Vaccine Market include:

Early Detection and Screening

Monoclonal Antibodies and Therapeutic Vaccines

Safety Concerns

Insurance and Reimbursement Issues

Personalized Medicine

Pharmacogenomics

Vaccine Strategies

Economic Conditions and Vaccine Discovery

Global Pharmaceutical Industry

CHAPTER ONE: EXECUTIVE SUMMARY: Introduction; Disease Burden; Scope and Methodology; Size and Growth of the Market; Issues and Trends Affecting Market; Leading Competitors
CHAPTER TWO: INTRODUCTION: Introduction; Cancer Descriptions; Timeline of Cancer Vaccine Developments; History and Growth of the Cancer Treatment Market; Types of Vaccines; Types of Therapeutic Vaccines; Industry Structure; Demographics and Statistics; Tobacco Use and Obesity Increases Cancer Risk
CHAPTER THREE: CERVICAL CANCER VACCINES: Overview; Description of Vaccines on the Market; Description of Vaccines in Development; Market Summary; Current and Potential Competitors and Analysis, 2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES: Overview; Description of Vaccines on the Market; Description of Vaccines in Development; Market Summary; Potential Competitors and Analysis, 2015
CHAPTER FIVE: LUNG CANCER VACCINES: Overview; Description of Vaccines in Development; Market Summary; Potential Competitors and Analysis, 2015
CHAPTER SIX: LYMPHOMA VACCINES: Overview; Description of Vaccines in Development; BiovaxID; MyVax; Market Summary; Potential Competitors and Analysis, 2015
CHAPTER SEVEN: MELANOMA VACCINES: Overview; Description of Vaccines on the Market; Description of Vaccines in Development; MVAX; Allovectin-7; MDX-1379 with Combination Treatment MDX-010; Oncophage; MAGE-A3 ASCI; ALVAC Vaccine; HyperAcute Melanoma; Market Summary; Potential Competitors and Analysis, 2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES: Overview; Description of Vaccines on the Market; Provenge; Description of Vaccines in Development; DCVax-Prostate; GVAX; PROSTVAC-VF; TroVAX; Onyvax-P; MVA-BN Prostate; HyperAcute Prostate; NeuVax; MKC1106-PP; Market Summary; Potential Competitors and Analysis, 2015
CHAPTER NINE: BREAST CANCER VACCINES: Overview; Description of Vaccines in Development; Stimuvax; NeuVax; GVAX; AVX701 Vaccine; MVA-BN HER2; Lapuleucel-T; CDX-1307-02; Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine; MKC1106-PP; Market Summary
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES: Overview; Description of Vaccines in Development; GI-4000; HyperAcute Pancreas; GVAX; Oncophage; CDX-1307; ANZ-100; DCVax; Market Summary
CHAPTER ELEVEN: RENAL CANCER VACCINES: Overview; Description of Vaccines on the Market; Oncophage; Description of Vaccines in Development; Oncophage; Reniale; TroVAX; IMA901; AGS-003; MDX-1106; MKC1106-PP; Market Summary; Potential Competitors and Analysis, 2015
CHAPTER TWELVE: BRAIN CANCER VACCINES: Overview; Glioblastoma; Neuroblastoma; Description of Vaccines in Development; DCVax-Brain; CDX-110; GliaAtak; Oncophage; Market Summary
CHAPTER THIRTEEN: BLADDER CANCER VACCINES: Overview; Description of Vaccines on the Market; BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-; Shire Pharmaceuticals); Description of Vaccines in Development; CDX-1307; Market Summary
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES: Overview; Description of Vaccines in Development; Abagovomab; OVax Autologous Cell Vaccine; Lapuleucel-T; Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine; MKC1106-PP; Market Summary
CHAPTER FIFTEEN: LEUKEMIA VACCINES: Overview; Description of Vaccines in Development; GVAX-Leukemia; GRNVAC1; PR1 Peptide Vaccine; Market Summary
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET: Introduction; Early Detection and Screening; Monoclonal Antibodies and Therapeutic Vaccines; Political and Social Pressure; Safety Concerns; Insurance and Reimbursement Issues; Personalized Medicine; Pharmacogenomics; Vaccine Strategies; Economic Conditions Affect Investing in Some Cancer Vaccine Discovery
CHAPTER SEVENTEEN THE CANCER VACCINE MARKET: MARKET FORECASTS: Overview; Total Market Size and Forecast; Prophylactic versus Therapeutic Cancer Vaccine Market Size; Market and Competitor Analysis
CHAPTER EIGHTEEN CANCER VACCINE CORPORATE PROFILES: Introduction; Accentia Biopharmaceuticals, Inc.; Antigenics, Inc.; Avax Technologies, Inc.; Dendreon Corporation; GlaxoSmithKline plc; Merck & Company, Inc.; Northwest Biotherapeutics, Inc.; Oncothyreon, Inc; Vaccinogen, Inc.
APPENDIX: COMPANY NAMES AND ADDRESSES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY: Table 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015; Figure 1-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015; Figure 1-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015
CHAPTER TWO: INTRODUCTION: Table 2- Significant Cancer Vaccine Approvals, 2000-201; Table 2-2 World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both sexe; Figure 2-1 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020; Table 2-3 Total Cancer Incidence by Sex and Country, 2010 Estimates; Figure 2-2 Total Cancer Incidence by Sex and Country, 2010 Estimates; Table 2-4 World Population by Selected Geographical Region, 2010 - 2050; Figure 2-3 World Population by Selected Geographical Region, 2010-2050; Table 2-5 Percent Population Over 65 by Year and Region, 2010-2050; Figure 2-4 Estimated World Population by Age, 2010 and 2050; Table 2-6 Percent of Smokers by Country; Figure 2-5 Average Percent of Smokers Worldwide in Developed Regions; Table 2-7 Estimated Obesity by Country 2009 Estimates; Figure 2-6 Estimated Obesity by Country as a Portion of Total Population 2009 Estimates; Figure 2-7 Increases in Obesity by Country—2007 and 2009 Figures; Table 2-8 Life Expectancy at Birth by Selected Countries, 2006; Figure 2-8 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2006; Figure 2-9 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2006; Figure 2-10 United States Person-Years of Life Lost Due to Major Causes of Death, All Races, Both Sexes, 2006
CHAPTER THREE: CERVICAL CANCER VACCINES: Table 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010; Figure 3-1 Estimated World Incidence of Cervical Cancer by Country, 2010; Table 3-2 Cervical Cancer Vaccines Approved and in the Pipeline; Table 3-3 The Developing Cervical Cancer Vaccine Market, 2007-2015; Figure 3-2 The Developing Cervical Cancer Vaccine Market, 2007-2015; Table 3-4 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015; Figure 3-3 The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015; Figure 3-4 Product Sales by Year for Cervical Cancer Vaccines, 2007-2015
CHAPTER FOUR: COLON/RECTAL CANCER VACCINES: Table 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010; Figure 4-1 Estimated World Incidence of Colon/Rectal Cancer by Country, 2010; Table 4-2 Colon/Rectal Cancer Vaccines in the Pipeline
CHAPTER FIVE: LUNG CANCER VACCINES: Table 5-1 TYPES OF PRIMARY LUNG CANCER; Table 5-2 Estimated World Incidence of Lung Cancer by Country, 2010; Figure 5-1 Estimated World Incidence of Lung Cancer by Country, 2010; Table 5-3 Lung Cancer Vaccines in the Pipeline
CHAPTER SIX: LYMPHOMA VACCINES: Table 6-1 CLASSIFICATION OF NON-HODGKIN’S LYMPHOMAS; Table 6-2 Estimated World Incidence of Lymphoma by Country, 2010; Figure 6-1 Estimated World Incidence of Lymphoma by Country, 2010; Table 6-3 Lymphoma Vaccines in the Pipeline
CHAPTER SEVEN: MELANOMA VACCINES: Table 7-1 MALIGNANT CONDITIONS OF THE SKIN; Table 7-2 Estimated World Incidence of Melanoma by Country, 2010; Figure 7-1 Estimated World Incidence of Melanoma by Country, 2010; Table 7-3 Melanoma Vaccines in the Pipeline; Table 7-3 (continued) Melanoma Vaccines in the Pipeline; Table 7-4 The Developing Melanoma Vaccine Market, 2007-2015; Figure 7-2 The Developing Melanoma Vaccine Market, 2007-2015; Table 7-5 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015; Figure 7-3 The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015; Figure 7-4 Product Sales by Year for Developing Melanoma Vaccines, 2007-2015
CHAPTER EIGHT: PROSTATE CANCER VACCINES: Table 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010; Figure 8-1 Estimated World Incidence of Prostate Cancer by Country, 2010; Table 8-2 Prostate Cancer Vaccines in the Pipeline; Table 8-2 (continued) Prostate Cancer Vaccines in the Pipeline; Table 8-3 The Emerging Prostate Cancer Vaccine Market, 2010-2015; Figure 8-2 The Emerging Prostate Cancer Vaccine Market, 2010-2015; Table 8-4 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015; Figure 8-3 The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2015; Figure 8-4 Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2015
CHAPTER NINE: BREAST CANCER VACCINES: Table 9-1 Estimated World Incidence of Breast Cancer by Country, 2010; Figure 9-1 Estimated World Incidence of Breast Cancer by Country, 2010; Table 9-2 Breast Cancer Vaccines in the Pipeline
CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES: Table 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010; Figure 10-1 Estimated World Incidence of Gastrointestinal Cancer by Country, 2010; Table 10-2 Gastrointestinal Cancer Vaccines in the Pipeline
CHAPTER ELEVEN: RENAL CANCER VACCINES: Table 11-1 Estimated World Incidence of Renal Cancer by Country, 2010; Figure 11-1 Estimated World Incidence of Renal Cancer by Country, 2010; Table 11-2 Renal Cancer Vaccines in the Pipeline
CHAPTER TWELVE: BRAIN CANCER VACCINES: Table 12-1 Estimated World Incidence of Brain Cancer by Country, 2010; Figure 12-1 Estimated World Incidence of Brain Cancer by Country, 2010; Table 12-2 Brain Cancer Vaccines in the Pipeline
CHAPTER THIRTEEN: BLADDER CANCER VACCINES: Table 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010; Figure 13-1 Estimated World Incidence of Bladder Cancer by Country, 2010; Table 13-2 Bladder Cancer Vaccines in the Pipeline
CHAPTER FOURTEEN: OVARIAN CANCER VACCINES: Table 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010; Figure 14-1 Estimated World Incidence of Ovarian Cancer by Country, 2010; Table 14-2 Ovarian Cancer Vaccines in the Pipeline
CHAPTER FIFTEEN: LEUKEMIA VACCINES: Table 15-1 TYPES OF LEUKEMIA; Table 15-2 Estimated World Incidence of Leukemia by Country, 2010; Figure 15-1 Estimated World Incidence of Leukemia Cancer by Country, 2010; Table 15-3 Leukemia Vaccines in the Pipeline
CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET: Table 16-1 Cancer Detection Tests; Table 16-2 Early Safety Statistics Concerning HPV Vaccination
CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS: Table 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015; Figure 17-1 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2007-2015; Figure 17-2 Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2015; Figure 17-3 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets, 2007-2015 208; Figure 17-2 Cancer Vaccines: Prophylactic and Therapeutic Cancer Vaccine Markets by Percent, 2015
CANCER VACCINE CORPORATE PROFILE: COMPANY NAMES AND ADDRESSES

Talk to Robyn

00 1 718 213 49 04

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global Pharmaceutical Industry : Latest Reports

Vaccines - Global

$ 26 587
Industry report
March 2012
by Global Research & Data Services

This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for pasta in global markets. The analyses provide essential market information ...

Vaccines - Americas

$ 5 174
Industry report
March 2012
by Global Research & Data Services

This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for vaccines in American markets. The analyses provide essential market information ...

Vaccines - Top 10 Global Markets

$ 5 174
Industry report
March 2012
by Global Research & Data Services

This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for vaccines in top 10 global markets. The analyses provide essential market ...

Global Veterinary Vaccines Industry

February 2012 $ 4 500

Global Human Vaccines Industry

March 2012 $ 4 500

Pediatric Vaccines Market To 2017- Strateg ...

March 2012 $ 3 500

World Biological Drugs Market 2012-2022

February 2012 $ 2 654

Leading Anti-cancer Drugs And Associated M ...

February 2012 $ 2 654

Vaccine Production (trends, Techniques, Ke ...

February 2012 $ 2 500

Vaccines - Top 5 Asian Markets

March 2012 $ 2 514

More Reports:

Pharmaceutical in China (231)

Pharmaceutical in France (335)

Pharmaceutical in Germany (347)

Pharmaceutical in Italy (340)

Pharmaceutical in Japan (431)

Pharmaceutical in Spain (330)

Pharmaceut... in the United Kingdom (402)

Pharmaceut... in the United States (1292)

Company Reports

GlaxoSmithKline P.L.C.

GlaxoSmithKline PLC

Johnson And Johnson

Sanofi-Aventis Senegal

Novartis Inc.

Pfizer Inc.

AstraZeneca PLC

Abbott Laboratories

F. Hoffmann-La Roche Ltd.

Eli Lilly And Co.

Global Pharmaceutical Industry : Latest Downloads

U.S. Pharmaceutical Industry

Industry report
May 2012
31 pages
by Corporation

... Severe uncontrolled asthma periostin level zelboraf metastatic melanoma braf v600e mutation t-dm1 metastatic breast cancer her2 expression level mericitabine and danoprevir hepatitis c hcv ...

Pharmaceutical Market in Egypt and The United States

Industry report
April 2012
37 pages

... Infection is higher in those with cirrhosis than in those with chronic hepatitis. Hcv is the dominant viral cause of hcc and it contributed to the increasing incidence of hcc during the past 2 decades ...

World Pharmaceutical Industry Analysis

Industry report
April 2012
84 pages

... In the Drug & cosmetics act That mandates all pharmaceutical units to comply to who gmp standards. This was strictly implemented from june 2005 despite several pleas by smes. As per the new manufacturing ...